These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33176396)

  • 1. Assessing the accuracy of conventional gadolinium-enhanced breast MRI in measuring the nodal response to neoadjuvant chemotherapy (NAC) in breast cancer.
    Murphy LC; Quinn EM; Razzaq Z; Brady C; Livingstone V; Duddy L; Barry J; Redmond HP; Corrigan MA
    Breast J; 2020 Nov; 26(11):2151-2156. PubMed ID: 33176396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is Breast Magnetic Resonance Imaging an Accurate Predictor of Nodal Status After Neoadjuvant Chemotherapy?
    Cortina CS; Gottschalk N; Kulkarni SA; Karst I
    J Surg Res; 2021 Jan; 257():412-418. PubMed ID: 32892139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy.
    Javid S; Segara D; Lotfi P; Raza S; Golshan M
    Ann Surg Oncol; 2010 Jul; 17(7):1841-6. PubMed ID: 20143266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast MRI and tumour biology predict axillary lymph node response to neoadjuvant chemotherapy for breast cancer.
    Al-Hattali S; Vinnicombe SJ; Gowdh NM; Evans A; Armstrong S; Adamson D; Purdie CA; Macaskill EJ
    Cancer Imaging; 2019 Dec; 19(1):91. PubMed ID: 31878958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
    Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
    Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computed tomography reconstruction for evaluating response in axillary lymph nodes of breast cancer after neoadjuvant chemotherapy.
    Wang L; Li Y; Li J; Wang T; Xie Y; He Y; Fan Z; Ouyang T
    Clin Transl Oncol; 2021 Feb; 23(2):240-245. PubMed ID: 32519177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of breast ultrasonography and MRI in the prediction of lymph node status after neoadjuvant chemotherapy for breast cancer.
    Ha SM; Cha JH; Kim HH; Shin HJ; Chae EY; Choi WJ
    Acta Radiol; 2017 Oct; 58(10):1198-1205. PubMed ID: 28350255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of axillary nodal imaging by magnetic resonance imaging based on breast cancer subtype after neoadjuvant chemotherapy.
    Steiman J; Soran A; McAuliffe P; Diego E; Bonaventura M; Johnson R; Ahrendt G; McGuire K
    J Surg Res; 2016 Jul; 204(1):237-41. PubMed ID: 27451892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axillary Nodal Burden Assessed with Pretreatment Breast MRI Is Associated with Failed Sentinel Lymph Node Identification after Neoadjuvant Chemotherapy for Breast Cancer.
    Kim WH; Kim HJ; Park CS; Lee J; Park HY; Jung JH; Kim WW; Chae YS; Lee SJ; Kim SH
    Radiology; 2020 May; 295(2):275-282. PubMed ID: 32125253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refining the Performance of Sentinel Lymph Node Biopsy Post-neoadjuvant Chemotherapy in Patients with Pathologically Proven Pre-treatment Node-positive Breast Cancer: An Update for Clinical Practice.
    El Hage Chehade H; Headon H; Kasem A; Mokbel K
    Anticancer Res; 2016 Apr; 36(4):1461-71. PubMed ID: 27069121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Axillary Response to Neoadjuvant Chemotherapy: Breast MRI and US in Patients with Node-Positive Breast Cancer.
    Kim R; Chang JM; Lee HB; Lee SH; Kim SY; Kim ES; Cho N; Moon WK
    Radiology; 2019 Oct; 293(1):49-57. PubMed ID: 31407967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The feasibility and the role of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer].
    Péley G; Török K; Farkas E; Mátrai Z; Horváth Z; Sinkovics I; Hitre E; Rényi-Vámos F; Orosz Z; Köves I
    Magy Onkol; 2006; 50(1):19-23. PubMed ID: 16617379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of axillary response by monitoring with ultrasound and MRI during and after neoadjuvant chemotherapy in breast cancer patients.
    Eun NL; Son EJ; Gweon HM; Kim JA; Youk JH
    Eur Radiol; 2020 Mar; 30(3):1460-1469. PubMed ID: 31802216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative axillary lymph node evaluation in breast cancer patients by breast magnetic resonance imaging (MRI): Can breast MRI exclude advanced nodal disease?
    Hyun SJ; Kim EK; Moon HJ; Yoon JH; Kim MJ
    Eur Radiol; 2016 Nov; 26(11):3865-3873. PubMed ID: 26843011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Routine Axillary Imaging Necessary in Clinically Node-Negative Patients Undergoing Neoadjuvant Chemotherapy?
    Barrio AV; Mamtani A; Eaton A; Brennan S; Stempel M; Morrow M
    Ann Surg Oncol; 2017 Mar; 24(3):645-651. PubMed ID: 28130619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is it always necessary to perform an axillary lymph node dissection after neoadjuvant chemotherapy for breast cancer?
    Osorio-Silla I; Gómez Valdazo A; Sánchez Méndez JI; York E; Díaz-Almirón M; Gómez Ramírez J; Rivas Fidalgo S; Oliver JM; Álvarez CM; Hardisson D; Díaz Miguel M; Lobo F; Díaz Domínguez J
    Ann R Coll Surg Engl; 2019 Mar; 101(3):186-192. PubMed ID: 30421628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer.
    Weber JJ; Jochelson MS; Eaton A; Zabor EC; Barrio AV; Gemignani ML; Pilewskie M; Van Zee KJ; Morrow M; El-Tamer M
    J Am Coll Surg; 2017 Dec; 225(6):740-746. PubMed ID: 28919579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine use of standard breast MRI compared to axillary ultrasound for differentiating between no, limited and advanced axillary nodal disease in newly diagnosed breast cancer patients.
    van Nijnatten TJA; Ploumen EH; Schipper RJ; Goorts B; Andriessen EH; Vanwetswinkel S; Schavemaker M; Nelemans P; de Vries B; Beets-Tan RGH; Smidt ML; Lobbes MBI
    Eur J Radiol; 2016 Dec; 85(12):2288-2294. PubMed ID: 27842679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
    Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
    Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI Volume Changes of Axillary Lymph Nodes as Predictor of Pathologic Complete Responses to Neoadjuvant Chemotherapy in Breast Cancer.
    Cattell RF; Kang JJ; Ren T; Huang PB; Muttreja A; Dacosta S; Li H; Baer L; Clouston S; Palermo R; Fisher P; Bernstein C; Cohen JA; Duong TQ
    Clin Breast Cancer; 2020 Feb; 20(1):68-79.e1. PubMed ID: 31327729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.